HER2-directed therapies, including monoclonal antibodies, ADCs, and TKIs, have improved survival in HER2-positive breast cancer patients. Clinical trials like CLEOPATRA, DESTINY-Breast01, and ...
Tucatinib combined with trastuzumab and pertuzumab extended PFS in HER2-positive metastatic breast cancer patients, showing a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results